A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

Clinical trial NCT07253142 · RECRUITING

Trial details

NCT number: NCT07253142
Sponsor: Shanghai Henlius Biotech
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Small Cell Lung Cancer

Start date: 2026-02-05
Primary completion: 2027-06-18
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.